Quadrant Private Wealth Management LLC Cuts Stock Position in AbbVie Inc. $ABBV

Quadrant Private Wealth Management LLC trimmed its position in shares of AbbVie Inc. (NYSE:ABBV) by 1.4% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 19,275 shares of the company’s stock after selling 267 shares during the quarter. Quadrant Private Wealth Management LLC’s holdings in AbbVie were worth $3,578,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Marshall & Sullivan Inc. WA purchased a new position in shares of AbbVie in the second quarter valued at approximately $25,000. TD Capital Management LLC lifted its holdings in AbbVie by 82.9% during the 1st quarter. TD Capital Management LLC now owns 128 shares of the company’s stock worth $27,000 after buying an additional 58 shares in the last quarter. Spurstone Advisory Services LLC purchased a new position in AbbVie in the 2nd quarter valued at approximately $28,000. Cypress Capital Management LLC WY purchased a new position in AbbVie in the 1st quarter valued at approximately $35,000. Finally, Bear Mountain Capital Inc. grew its stake in shares of AbbVie by 480.6% in the second quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock worth $40,000 after acquiring an additional 173 shares in the last quarter. 70.23% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, EVP Azita Saleki-Gerhardt sold 42,370 shares of the stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $198.42, for a total value of $8,407,055.40. Following the transaction, the executive vice president directly owned 177,292 shares of the company’s stock, valued at $35,178,278.64. This trade represents a 19.29% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 0.25% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently issued reports on ABBV shares. Wall Street Zen upgraded AbbVie from a “hold” rating to a “buy” rating in a research note on Saturday, October 25th. Morgan Stanley boosted their target price on AbbVie from $250.00 to $255.00 and gave the stock an “overweight” rating in a research note on Friday, August 1st. Daiwa Capital Markets raised AbbVie from a “neutral” rating to an “outperform” rating and set a $214.00 price target on the stock in a research report on Thursday, August 7th. HSBC set a $225.00 price objective on AbbVie in a research report on Thursday, October 2nd. Finally, Bank of America raised their target price on shares of AbbVie from $220.00 to $251.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $236.57.

AbbVie Trading Down 0.1%

ABBV opened at $218.92 on Friday. AbbVie Inc. has a one year low of $163.81 and a one year high of $244.81. The company has a market cap of $386.74 billion, a P/E ratio of 104.25, a PEG ratio of 1.42 and a beta of 0.50. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.61 and a current ratio of 0.74. The business’s 50-day simple moving average is $223.24 and its 200-day simple moving average is $202.30.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.09. The business had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The business’s quarterly revenue was up 9.1% on a year-over-year basis. During the same quarter last year, the company earned $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, equities research analysts expect that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be given a dividend of $1.73 per share. The ex-dividend date is Friday, January 16th. This represents a $6.92 annualized dividend and a dividend yield of 3.2%. This is a boost from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s payout ratio is presently 524.24%.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.